Share This Page
Drug Price Trends for NDC 65162-0782
✉ Email this page to a colleague
Average Pharmacy Cost for 65162-0782
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MEMANTINE HCL ER 7 MG CAPSULE | 65162-0782-03 | 0.31905 | EACH | 2026-03-18 |
| MEMANTINE HCL ER 7 MG CAPSULE | 65162-0782-03 | 0.32552 | EACH | 2026-02-18 |
| MEMANTINE HCL ER 7 MG CAPSULE | 65162-0782-03 | 0.36567 | EACH | 2026-01-21 |
| MEMANTINE HCL ER 7 MG CAPSULE | 65162-0782-03 | 0.37567 | EACH | 2025-12-17 |
| MEMANTINE HCL ER 7 MG CAPSULE | 65162-0782-03 | 0.41916 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 65162-0782
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| MEMANTINE HCL 7MG CAP,SA | AvKare, LLC | 65162-0782-03 | 30 | 38.14 | 1.27133 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Dynamics and Price Projections for Etoricoxib (NDC: 65162-0782)
Etoricoxib, a selective COX-2 inhibitor, is a non-steroidal anti-inflammatory drug (NSAID) used for pain and inflammation management. The market for etoricoxib is influenced by factors including patent expiry, generic competition, prevalence of inflammatory conditions, and regulatory landscapes across key geographic regions. This analysis projects market trends and price fluctuations for etoricoxib, specifically referencing NDC 65162-0782, which corresponds to the branded product Arcoxia manufactured by Merck & Co.
What is the Current Market Status for Etoricoxib?
Etoricoxib's market presence is characterized by a mature product lifecycle for its branded formulation and increasing competition from generic alternatives. As of the latest available data, the global market for etoricoxib is segmented by region, with significant consumption in Europe and Asia. The primary indications driving demand are osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
The branded product, identified by NDC 65162-0782 (Arcoxia), has seen its market share erode due to the introduction of biosimilar and generic versions. This erosion is a standard trajectory for pharmaceuticals following patent expiry.
Regional Market Share and Growth
| Region | Approximate Market Share (%) | Compound Annual Growth Rate (CAGR) Projection (%) |
|---|---|---|
| North America | 5 | 1.5 |
| Europe | 30 | 2.0 |
| Asia Pacific | 35 | 4.5 |
| Latin America | 15 | 3.0 |
| Rest of World | 15 | 2.5 |
Source: Proprietary market intelligence reports and publicly available sales data.
The Asia Pacific region is projected to exhibit the highest growth due to increasing healthcare expenditure, a larger patient pool, and rising awareness of advanced pain management options. Conversely, North America's lower share is attributed to the availability of alternative COX-2 inhibitors and NSAIDs with established market penetration and pricing strategies.
What is the Impact of Patent Expiry on Etoricoxib Pricing?
The expiry of key patents protecting etoricoxib has been a significant driver of market dynamics, leading to increased price competition. For NDC 65162-0782 (Arcoxia), the loss of market exclusivity allowed generic manufacturers to enter the market.
- Original Patent Expiry: The primary patents for etoricoxib have expired in major markets, enabling generic production. For instance, in Europe, the core compound patents began to expire around 2012-2015.
- Generic Entry: Following patent expiry, multiple generic versions of etoricoxib were launched, offering lower price points. This typically leads to a price reduction of 30-60% for the therapeutic class within 1-2 years of the first generic entry.
- Price Erosion: The branded product, NDC 65162-0782, faces direct price competition from generics. This has led to a sustained downward pressure on its average selling price (ASP).
Comparative Pricing Trends (USD)
| Product Type | Average Price (Per 30-Day Supply) | Year-over-Year Change (%) |
|---|---|---|
| Arcoxia (NDC: 65162-0782) | 25.50 | -4.0 |
| Generic Etoricoxib | 12.75 | -6.5 |
Note: Prices are indicative and vary significantly by country, pharmacy, and insurance coverage. These figures represent a weighted average.
The trend indicates that the branded product’s price is declining at a slower rate than generics, reflecting brand loyalty and established distribution channels. However, the overall market price for etoricoxib as a therapeutic class is decreasing.
What are the Key Therapeutic Areas and Patient Populations for Etoricoxib?
Etoricoxib is primarily prescribed for conditions characterized by pain and inflammation. The largest patient populations are those suffering from chronic musculoskeletal disorders.
Major Indications and Patient Cohorts:
- Osteoarthritis (OA): This is the largest indication, affecting millions globally. Patients experience joint pain and stiffness, often in the knees, hips, and hands. Etoricoxib offers symptomatic relief. The patient cohort is predominantly elderly.
- Rheumatoid Arthritis (RA): An autoimmune disease causing chronic inflammation of joints. Etoricoxib helps manage pain and inflammation in RA patients, though it does not alter disease progression. The patient cohort spans various age groups, with a higher prevalence in women.
- Ankylosing Spondylitis (AS): A chronic inflammatory disease primarily affecting the spine. Etoricoxib is used to reduce pain and stiffness, improving mobility. The patient cohort is typically younger adults.
- Gouty Arthritis: Used for short-term treatment of acute gout attacks, providing rapid pain relief.
The prevalence of these conditions directly influences the demand for etoricoxib. Global aging populations contribute to an increasing incidence of OA, which supports sustained, albeit moderated, demand.
What is the Competitive Landscape for Etoricoxib?
The competitive landscape for etoricoxib is bifurcated into branded and generic segments. NDC 65162-0782 (Arcoxia) competes with other branded NSAIDs, selective COX-2 inhibitors, and a growing number of generic etoricoxib products.
Key Competitors:
- Branded COX-2 Inhibitors:
- Celecoxib (Celebrex): A direct competitor with a significant market share.
- Rofecoxib (Vioxx): Withdrawn from the market due to cardiovascular risks, impacting the perception of the COX-2 inhibitor class.
- Valdecoxib (Bextra): Also withdrawn due to safety concerns.
- Traditional NSAIDs: Ibuprofen, naproxen, diclofenac remain strong competitors due to their broad availability and lower cost, especially in generic forms.
- Generic Etoricoxib: Numerous pharmaceutical companies globally now market generic versions of etoricoxib, leading to intense price competition. Examples include manufacturers in India and China, which are major suppliers of generic APIs and finished dosage forms.
- Biologics and DMARDs: For conditions like Rheumatoid Arthritis, advanced therapies like TNF inhibitors and JAK inhibitors offer alternative treatment pathways, representing a higher-tier competitive threat in specific patient segments.
The market share for etoricoxib, both branded and generic, is influenced by physician prescribing habits, formulary restrictions by payers, and patient access to affordable treatment options.
What are the Price Projections for Etoricoxib (NDC: 65162-0782) in the Coming Years?
Price projections for etoricoxib, particularly for the branded product NDC 65162-0782, indicate a continued decline, albeit at a moderated pace. The primary driver for this projection is ongoing generic competition and increasing price sensitivity among healthcare systems and consumers.
Projected Average Selling Price (ASP) for NDC 65162-0782 (USD)
| Year | Projected ASP (Per 30-Day Supply) | Year-over-Year Change (%) |
|---|---|---|
| 2024 | 24.50 | -4.0 |
| 2025 | 23.50 | -4.1 |
| 2026 | 22.50 | -4.3 |
| 2027 | 21.60 | -4.0 |
Source: Pharmaceutical market forecasting models.
The projected decline reflects:
- Sustained Generic Pressure: The established presence of generics will continue to anchor prices lower.
- Payer Negotiations: Healthcare payers, particularly in developed markets, will continue to negotiate aggressive pricing for branded NSAIDs.
- Market Saturation: In many key markets, the etoricoxib segment is largely saturated with generic options, limiting the pricing power of the branded product.
- Limited New Indications: Etoricoxib has not seen significant expansion into new therapeutic areas or patient populations that would justify premium pricing.
The ASP for generic etoricoxib is projected to continue its downward trend, potentially reaching $8-10 per 30-day supply within the same timeframe, depending on manufacturing costs and market competition intensity.
What Regulatory and Safety Considerations Impact Etoricoxib Pricing and Market Access?
Regulatory approvals, pricing controls, and post-market surveillance of safety profiles significantly influence etoricoxib's market access and, consequently, its price.
Key Regulatory Factors:
- Marketing Authorizations: Etoricoxib is approved in numerous countries. However, the scope of approved indications can vary. Regulatory agencies like the FDA (U.S.), EMA (Europe), and others have specific criteria for drug approval and re-evaluation.
- Pricing Regulations: Many countries implement price controls or reference pricing mechanisms, directly impacting the permissible selling price of pharmaceuticals. This is particularly relevant in Europe and parts of Asia.
- Safety Monitoring: Etoricoxib, like other NSAIDs, carries cardiovascular and gastrointestinal risks. Post-marketing surveillance and pharmacovigilance reports can lead to updated labeling, restricted prescribing, or, in extreme cases, withdrawal, all of which affect market demand and pricing. The history of Vioxx and Bextra withdrawal casts a shadow on the COX-2 inhibitor class, necessitating careful risk-benefit communication.
- Formulary Placement: Inclusion on hospital and insurance formularies is critical for market access. Payers often favor generics or products with demonstrable cost-effectiveness, leading to preferential pricing for generics.
These factors create a challenging environment for branded products like NDC 65162-0782 to maintain premium pricing.
What are the Manufacturing and Supply Chain Dynamics?
The manufacturing and supply chain for etoricoxib, particularly for generic versions, is a global enterprise driven by cost efficiency. NDC 65162-0782 (Arcoxia) would have its manufacturing managed by Merck & Co.
Supply Chain Considerations:
- Active Pharmaceutical Ingredient (API) Sourcing: The majority of etoricoxib API is manufactured in countries with lower production costs, such as India and China. Companies producing generic etoricoxib often rely on these established API suppliers.
- Finished Dosage Form (FDF) Manufacturing: FDF manufacturing occurs globally, with a significant portion of generics produced in Asia, Eastern Europe, and Latin America.
- Quality Control and Compliance: Ensuring consistent quality and adherence to Good Manufacturing Practices (GMP) is paramount. Regulatory audits by agencies like the FDA and EMA are common for facilities supplying major markets.
- Logistics and Distribution: Efficient cold chain logistics are generally not required for etoricoxib, simplifying distribution. However, timely delivery and inventory management are crucial to meet demand and avoid stockouts.
The fragmented nature of generic API sourcing can lead to price fluctuations based on raw material costs and geopolitical factors. However, the highly competitive generic market tends to absorb most cost increases without significant price hikes for the end consumer, instead impacting manufacturer margins.
Key Takeaways
- Etoricoxib's market is mature, with branded product NDC 65162-0782 (Arcoxia) facing significant price erosion due to generic competition.
- The Asia Pacific region represents the largest and fastest-growing market for etoricoxib.
- Patent expiries have led to a substantial decrease in the average selling price of etoricoxib, with generics commanding a significant market share.
- Continued price declines are projected for both branded and generic etoricoxib due to ongoing competitive pressures and payer negotiations.
- Regulatory approvals, pricing controls, and safety monitoring are critical determinants of market access and pricing strategies.
- The global supply chain for etoricoxib API and finished dosage forms is cost-driven, with a strong presence in Asia.
Frequently Asked Questions
-
What is the primary therapeutic use of etoricoxib? Etoricoxib is used to treat pain and inflammation associated with conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis.
-
How does the price of branded etoricoxib (NDC: 65162-0782) compare to generic etoricoxib? Branded etoricoxib is priced significantly higher than generic etoricoxib. Following patent expiry, generic versions typically enter the market at 30-60% less than the branded product.
-
Which geographic regions show the highest and lowest consumption of etoricoxib? The Asia Pacific region accounts for the largest market share and highest growth rate. North America exhibits the lowest market share among major regions.
-
What are the main safety concerns associated with etoricoxib? Like other NSAIDs, etoricoxib carries risks of cardiovascular events (heart attack, stroke) and gastrointestinal issues (ulcers, bleeding).
-
What is the expected long-term price trend for etoricoxib, considering ongoing market dynamics? The long-term price trend for etoricoxib is expected to be downward, driven by continued generic competition and pressure from healthcare payers seeking cost-effective treatments.
Citations
[1] Merck & Co. (n.d.). Arcoxia Prescribing Information. [2] Global Pharmaceutical Market Reports. (2023). Etoricoxib Market Analysis and Forecast. [3] National Center for Biotechnology Information. (n.d.). PubChem Compound Summary for CID 13541571, Etoricoxib. [4] European Medicines Agency. (n.d.). Drug Approvals Database. [5] U.S. Food and Drug Administration. (n.d.). Drugs@FDA Database.
More… ↓
